Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.

Vo MC, Nguyen-Pham TN, Lee HJ, Jung SH, Choi NR, Hoang MD, Kim HJ, Lee JJ.

Oncotarget. 2017 Jul 11;8(28):46047-46056. doi: 10.18632/oncotarget.17517.

2.

Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.

Comte D, Karampetsou MP, Yoshida N, Kis-Toth K, Kyttaris VC, Tsokos GC.

Arthritis Rheumatol. 2017 May;69(5):1035-1044. doi: 10.1002/art.40038.

PMID:
28076903
3.

Tolerogenic effect of mouse fibroblasts on dendritic cells.

Khosravi-Maharlooei M, Pakyari M, Jalili RB, Salimi-Elizei S, Lai JC, Poormasjedi-Meibod M, Kilani RT, Dutz J, Ghahary A.

Immunology. 2016 May;148(1):22-33. doi: 10.1111/imm.12584. Epub 2016 Feb 8.

4.

Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model.

Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, Xiang G, Huang L.

Mol Ther. 2016 Feb;24(2):364-74. doi: 10.1038/mt.2015.165. Epub 2015 Sep 3.

5.

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.

Hoang MD, Jung SH, Lee HJ, Lee YK, Nguyen-Pham TN, Choi NR, Vo MC, Lee SS, Ahn JS, Yang DH, Kim YK, Kim HJ, Lee JJ.

Chonnam Med J. 2015 Apr;51(1):1-7. doi: 10.4068/cmj.2015.51.1.1. Epub 2015 Apr 14. Review.

6.

Dendritic cell cancer vaccines: from the bench to the bedside.

Katz T, Avivi I, Benyamini N, Rosenblatt J, Avigan D.

Rambam Maimonides Med J. 2014 Oct 29;5(4):e0024. doi: 10.5041/RMMJ.10158. eCollection 2014 Oct.

7.

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA.

Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Review.

8.

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM.

Mol Ther. 2013 Nov;21(11):2122-9. doi: 10.1038/mt.2013.154. Epub 2013 Jul 8.

9.
10.

Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Danylesko I, Beider K, Shimoni A, Nagler A.

Clin Dev Immunol. 2012;2012:753407. doi: 10.1155/2012/753407. Epub 2012 May 10. Review.

11.

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ.

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15. Review.

12.

Cellular immunotherapy using dendritic cells against multiple myeloma.

Nguyen-Pham TN, Lee YK, Lee HJ, Kim MH, Yang DH, Kim HJ, Lee JJ.

Korean J Hematol. 2012 Mar;47(1):17-27. doi: 10.5045/kjh.2012.47.1.17. Epub 2012 Mar 28.

13.

CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q.

Cancer Immunol Immunother. 2012 Apr;61(4):561-71. doi: 10.1007/s00262-011-1123-2. Epub 2011 Oct 15.

14.

Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW.

Clin Cancer Res. 2011 Sep 15;17(18):5945-52. doi: 10.1158/1078-0432.CCR-11-0970. Epub 2011 Aug 3.

15.

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Barber A, Meehan KR, Sentman CL.

Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6.

16.

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.

Blood. 2011 Jan 13;117(2):393-402. doi: 10.1182/blood-2010-04-277137. Epub 2010 Oct 28.

17.

Novel immunotherapies.

Yi Q.

Cancer J. 2009 Nov-Dec;15(6):502-10. doi: 10.1097/PPO.0b013e3181c51f0d. Review.

18.

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F.

Blood. 2010 Feb 11;115(6):1185-93. doi: 10.1182/blood-2009-06-228676. Epub 2009 Dec 11.

19.

Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q.

Cancer Res. 2008 Oct 15;68(20):8456-64. doi: 10.1158/0008-5472.CAN-08-2213.

Supplemental Content

Support Center